Molecular Profile | KRAS G12D PTEN loss TP53 V216M |
Therapy | MLN0128 + PD-0325901 |
Indication/Tumor Type | colorectal cancer |
Response Type | no benefit |
Create By | tyin |
Update By | tyin |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | KRAS G12D PTEN loss TP53 V216M | colorectal cancer | no benefit | MLN0128 + PD-0325901 | Preclinical - Pdx | Actionable | In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PTEN loss, and TP53 V216M (PMID: 26272063). | 26272063 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(26272063) | MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. | Full reference... |